AIDX 20/20 Biolabs, Inc.

Overview and Growth

Fiscal 2025 results for 20/20 Biolabs, Inc. combined $2.05M of revenue with net loss of $3.74M and an operating cash outflow of $1.92M. At $2.05M, the top line establishes the operating scale supporting the company’s profit and cash-flow profile. Compared with $1.75M in fiscal 2024, revenue recorded a 16.7% year-over-year increase. On a per-share basis, diluted EPS was -$0.76, which connects the reported earnings outcome with the company’s diluted share count. Diluted shares averaged 4.93M; this is the reported share base over which the company’s diluted per-share earnings were spread. Diluted shares moved 2.7% from 4.80M in fiscal 2024, leaving the current share base higher year over year. The company employed $4.14M of total assets, the balance-sheet base supporting its current operating and cash-flow results. The revenue-to-assets relationship was 0.49x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

The first profit layer was $604.54K of gross profit, the amount available after reported direct revenue costs to absorb operating expenses. Gross margin was 29.6%, so that share of each revenue unit remained after the cost of revenue reported for the period. The reported operating result was an operating loss of $3.33M, reflecting costs that exceeded gross profit. Relative to revenue, the operating deficit measured 162.9%, showing the shortfall after operating costs. The company ended the period with a net loss of $3.74M, extending the operating result through all remaining items. Net margin was -182.8%, reflecting a loss equal to 182.8% of reported revenue. EBITDA was negative $3.27M, showing a deficit before interest, taxes, depreciation, and amortization. Relative to total assets, the net loss represented 90.4%. The net loss narrowed to $3.74M from $5.55M in fiscal 2024.

Liquidity and Capital Structure

Total assets were $4.14M, supported by $4.16M of liabilities and -$19.23K of shareholder equity. The company reported negative equity of -$19.23K, a capital deficit that reduces its ability to absorb losses through book equity. At period end, current assets of $1.47M compared with current liabilities of $2.46M, defining the company’s short-term resource position. The current ratio was 0.6x; current liabilities exceeded current assets, leaving a short-term liquidity deficit. Cash and equivalents totaled $1.03M, identifying the most liquid reported component available within the broader current-asset balance. The cash balance equaled 41.7% of current liabilities, showing how much near-term coverage came from cash alone. The equity-to-assets relationship was -0.5%, placing book capital against the total resource base. The liabilities-to-assets relationship was 100.5%, placing reported obligations against the full positive asset balance. The cash-to-assets relationship was 24.8%, comparing reported cash and equivalents with the full positive asset balance. The asset base changed 15.4% from $3.58M in fiscal 2024, leaving current total assets higher year over year. Book equity was 101.3% lower than fiscal 2024 equity of $1.51M, showing how shareholder capital changed year over year. Compared with $1.78M in fiscal 2024, the current cash balance moved 42.5% and finished lower.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $1.92M, showing that operations absorbed cash during the period. The operating cash outflow narrowed to $1.92M from $2.60M in fiscal 2024.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.